HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by LeWitt, P. A. Articles by Calne, D. B. Search for Related Content PubMed PubMed Citation Articles by LeWitt, P. A. Articles by Calne, D. B.

Lisuride versus bromocriptine treatment in Parkinson disease

A double-blind study

Experimental Therapeutics Branch (Drs. LeWitt, Gopina- than, Ward, Durso, and Calne), the Office of Biometry and Field Studies (Dr. Dambrosia), National Institute of Neurological and Communicative Disorders and Stroke, and the Laboratory of Neurophysiology (Dr. Sanes), National Institute of Mental Health, Bethesda, MD.

Twenty-eight parkinsonian patients were studied in a double-blind, crossover comparison of lisuride and bromocriptine. All but two patients completed the study, with each drug adjusted to an optimal dose (mean daily intake of 4.5 mg for lisuride and 56.5 mg for bromocriptine). Treatment with each drug was given for 7 to 10 weeks; three assessments were made at biweekly intervals with optimal dose levels. Conventional antiparkinsonian medications, including lev- odopa, were not changed. Efficacy and adverse effects were assessed by objective and subjective techniques. The only significant difference was slightly better control of akinesia with bromocriptine. There was considerable variability in the optimal dose of each drug, though the clinical profile of lisuride was quite similar to that of bromocriptine.

Address correspondence and reprint requests to Dr. Calne, Building 10, Room 6D20, National Institutes of Health, Bethesda, MD 20205.

Accepted for publication July 2, 1981.

This article has been cited by other articles:

				D. B. Calne Treatment of Parkinson's Disease N. Engl. J. Med., September 30, 1993; 329(14): 1021 - 1027. [Full Text]